

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3298.1003-000		APPLICATION NO. 10/087,996	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 22, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Brian Leyland-Jones		FILING DATE February 28, 2002	
		EXAMINER Not yet assigned		CONFIRMATION NO. 2676	
				GROUP 1641	

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
AL	AA	5,830,672	11-03-1998	Wainer <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
AL	AL	WO 00/55624 A2	09-21-2000	Brian Leyland-Jones		
1	AM	WO 95/04757 A1	02-16-1995	Board of Regents, University of Texas System		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	AR	Wong, P.N., <i>et al.</i> "Syntheses of Caffeine Metabolites Derivatives for Measuring CYP1A2 Activity by ELISA," Proceedings of the 90th Annual Meeting of the American Association for Cancer Research, 40:53 (1999).
	AS	Iyer, L. and Ratain, M.J., "Pharmacogenetics and Cancer Chemotherapy," <i>European Journal of Cancer</i> , 34(10):1493-1499 (1998).
	AT	Innocenti, F., <i>et al.</i> "Pharmacogenetics of Anticancer Agents: Lessons for Amonafide and Irinotecan," <i>Drug Metabolism and Disposition</i> , 29(4 part 2): 596-600 (2001).

EXAMINER <i>Amy R. Lewis</i>	DATE CONSIDERED 11/29/04
---------------------------------	-----------------------------

APPLICATION NO.
10/087,996

FILING DATE
February 28, 2002

CONFIRMATION NO.
2676

GROUP
1641

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

August 5, 2004

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.

3298.1003-000

APPLICATION NO.

10/087,996

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

August 5, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR

Brian Leyland-Jones

FILING DATE

February 28, 2002

EXAMINER

Not yet assigned

CONFIRMATION NO.

2676

GROUP

1641

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

20	AU	Beste, G., <i>et al.</i> , "Small Antibody-Like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," <i>Proc. Natl. Sci.</i> , 96:1898-1903 (1999).
	AV	Rabbany, S. Y., <i>et al.</i> , "Optical Immunosensors," <i>Crit. Rev. Biomed. Eng.</i> , 22(5/6):307-346 (1994).
	AW	Wang, J., <i>et al.</i> , "Mismatch-Sensitive Hybridization Detection by Peptide Nucleic Acids Immobilized on a Quartz Crystal Microbalance," <i>Anal. Chem.</i> , 69(24):5200-5202 (1997).
	AX	Wong, P., <i>et al.</i> , "A Competitive Enzyme Linked Immunosorbent Assay for the Determination of <i>N</i> -acetyltransferase (NAT2) Phenotypes," <i>J. Pharm. Biomed. Anal.</i> , 13:1079-1086 (1995).
	AY	Desta, Z., <i>et al.</i> , "Effect of Clarithromycin on the Pharmacokinetics and Pharmacodynamics of Pimozide in Healthy Poor and Extensive Metabolizers of Cytochrome P450 2D6 (CYP2D6)," <i>Clin. Pharmacol. Ther.</i> , 65(1):10-20 (1999).
	AZ	Tang, B. K., <i>et al.</i> , "Caffeine as a Metabolic Probe: Validation of its Use for Acetylator Phenotyping," <i>Clin. Pharmacol. Ther.</i> , 49(6):648-657 (1991).
	AR2	Wolf, C. R., <i>et al.</i> , "Chapter 18. Cytochrome P450 CYP2D6," <i>Metabolic Polymorphisms and Susceptibility to Cancer</i> , 148:209-229 (1999).
	AS2	Kroemer, H. K., <i>et al.</i> , "Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism," <i>Life Sci.</i> , 56(26):2285-2298 (1995).
	AT2	Kenworthy, K. E., <i>et al.</i> , "CYP3A4 Drug Interactions: Correlation of 10 <i>In Vitro</i> Probe Substrates," <i>Br. J. Clin. Pharmacol.</i> , 48:716-727 (1999).
	AU2	Hirth, J., <i>et al.</i> , "The Effect of an Individual's Cytochrome CYP3A4 Activity on Docetaxel Clearance," <i>Clin. Cancer Res.</i> , 6:1255-1258 (2000).
	AV2	Thummel, K. E., <i>et al.</i> , " <i>In Vitro</i> and <i>In Vivo</i> Drug Interactions Involving Human CYP3A," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 38:389-430 (1998).

EXAMINER

DATE CONSIDERED